Development and characterization of interleukin-18-loaded biodegradable microspheres

International Journal of Pharmaceutics

Volumn 314, Issue 2, 2006, Pages 179-188

  Lagarce, F ^a   Garcion, E ^a,b   Faisant, N ^a   Thomas, O ^a   Kanaujia, P ^a   Menei, P ^a,b   Benoit, J P ^a  

^a INSERM   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Adjuvants; Cancer therapy; Controlled drug delivery systems; Cytokine release; Interleukin 18; Microspheres; Poly(lactic co glycolic acid)

Indexed keywords

INTERLEUKIN 18; IODINE 125; MACROGOL 400; MACROGOL 8000; MICROSPHERE; POLYGLACTIN; RESOMER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; BIODEGRADABILITY; BIOLOGICAL ACTIVITY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM TUMOR; CYTOTOXICITY; DRUG ACTIVITY; ENCAPSULATION; FLOW MEASUREMENT; IMPLANTATION; ISOTOPE LABELING; MICROENVIRONMENT; PARTICLE SIZE; PRIORITY JOURNAL; RELIABILITY; STEREOTAXIS; SUSTAINED DRUG RELEASE; VALIDATION PROCESS;

ABSORBABLE IMPLANTS; ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; DRUG CARRIERS; DRUG IMPLANTS; DRUG STABILITY; GLIOMA; INTERFERON TYPE II; INTERLEUKIN-18; LACTIC ACID; MICROSPHERES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS; RATS; SERUM ALBUMIN, BOVINE; SOLUBILITY; SPLEEN; TECHNOLOGY, PHARMACEUTICAL;

EID: 33646467926     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.07.029     Document Type: Article

References (49)

1. Ashley D.M., Faiola B., Nair S., Hale L.P., Bigner D.D., and Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186 (1997) 1177-1182
2. Aubert-Pouessel A., Venier-Julienne M.C., Clavreul A., Sergent M., Jollivet C., Montero-Menei C.N., Garcion E., Bibby D.C., Menei P., and Benoit J.P. In vitro study of GDNF release from biodegradable PLGA microspheres. J. Control. Release 95 (2004) 463-475
3. Barker C.F., and Billingham R.E. Immunologically privileged sites. Adv. Immunol. 25 (1977) 1-54
4. Benedetti S., Bruzzone M.G., Pollo B., DiMeco F., Magrassi L., Pirola B., Cirenei N., Colombo M.P., and Finocchiaro G. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene. Cancer Res. 59 (1999) 645-652
5. Benoit J.P., Faisant N., Venier-Julienne M.C., and Menei P. Development of microspheres for neurological disorders: from basics to clinical applications. J. Control. Release 65 (2000) 285-296
6. Bilati U., Allemann E., and Doelker E. Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm. 59 (2005) 375-388
7. Cao R., Farnebo J., Kurimoto M., and Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 13 (1999) 2195-2202
8. Chang B.S., Beauvais R.M., Arakawa T., Narhi L.O., Dong A., Aparisio D.I., and Carpenter J.F. Formation of an active dimer during storage of interleukin-1 receptor antagonist in aqueous solution. Biophys. J. 71 (1996) 3399-3406
9. Coughlin C.M., Salhany K.E., Wysocka M., Aruga E., Kurzawa H., Chang A.E., Hunter C.A., Fox J.C., Trinchieri G., and Lee W.M. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101 (1998) 1441-1452
10. Didenko V.V., Ngo H.N., Minchew C., and Baskin D.S. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J. Neurosurg. 96 (2002) 580-584
11. Dinarello C.A. Interleukin-18. Methods 19 (1999) 121-132
12. Ehtesham M., Kabos P., Kabosova A., Neuman T., Black K.L., and Yu J.S. The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res. 62 (2002) 5657-5663
13. Erden N., and Celebi N. Factors influencing release of salbutamol sulphate from poly(lactide-co-glycolide) microspheres prepared by water-in-oil-in-water emulsion technique. Int. J. Pharm. 137 (1996) 57-66
14. Geze A., Venier-Julienne M.C., Saulnier P., Varlet P., Daumas-Duport C., Devauchelle P., and Benoit J.P. Modulated release of IdUrd from poly(d,l-lactide-co-glycolide) microspheres by addition of poly(d,l-lactide) oligomers. J. Control. Release 58 (1999) 311-322
15. Glick R.P., Lichtor T., de Zoeten E., Deshmukh P., and Cohen E.P. Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45 (1999) 867-874
16. Golab J. Interleukin 18-interferon gamma inducing factor-a novel player in tumour immunotherapy?. Cytokine 12 (2000) 332-338
17. Graf M.R., Prins R.M., Poulsen G.A., and Merchant R.E. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery. J. Neuroimmunol. 140 (2003) 49-60
18. Gu Y., Kuida K., Tsutsui H., Ku G., Hsiao K., Fleming M.A., Hayashi N., Higashino K., Okamura H., Nakanishi K., Kurimoto M., Tanimoto T., Flavell R.A., Sato V., Harding M.W., Livingston D.J., and Su M.S. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme. Science 275 (1997) 206-209
19. Gutzmer R., Langer K., Mommert S., Wittmann M., Kapp A., and Werfel T. Human dendritic cells express the IL-18R and are chemoattracted to IL-18. J. Immunol. 171 (2003) 6363-6371
20. Herold-Mende C., Mueller M.M., Bonsanto M.M., Schmitt H.P., Kunze S., and Steiner H.H. Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer 98 (2002) 362-369
21. Herzyk D.J., Bugelski P.J., Hart T.K., and Wier P.J. Preclinical safety of recombinant human interleukin-18. Toxicol. Pathol. 31 (2003) 554-561
22. Ishida Y., Migita K., Izumi Y., Nakao K., Ida H., Kawakami A., Abiru S., Ishibashi H., Eguchi K., and Ishii N. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells. FEBS Lett. 569 (2004) 156-160
23. Johansen P., Men Y., Audran R., Corradin G., Merkle H.P., and Gander B. Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharm. Res. 15 (1998) 1103-1110
24. Komai-Koma M., Gracie J.A., Wei X.Q., Xu D., Thomson N., McInnes I.B., and Liew F.Y. Chemoattraction of human T cells by IL-18. J. Immunol. 170 (2003) 1084-1090
25. Liau L.M., Black K.L., Prins R.M., Sykes S.N., DiPatre P.L., Cloughesy T.F., Becker D.P., and Bronstein J.M. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J. Neurosurg. 90 (1999) 1115-1124
26. Liu B., Novick D., Kim S.H., and Rubinstein M. Production of a biologically active human interleukin 18 requires its prior synthesis as PRO-IL-18. Cytokine 12 (2000) 1519-1525
27. Maysinger D., Krieglstein K., Filipovic-Grcic J., Sendtner M., Unsicker K., and Richardson P. Microencapsulated ciliary neurotrophic factor: physical properties and biological activities. Exp. Neurol. 138 (1996) 177-188
28. Menei P., Daniel V., Montero-Menei C., Brouillard M., Pouplard-Barthelaix A., and Benoit J.P. Biodegradation and brain tissue reaction to poly(d,l-lactide-co-glycolide) microspheres. Biomaterials 14 (1993) 470-478
29. Mittal S., Cohen A., and Maysinger D. In vitro effects of brain derived neurotrophic factor released from microspheres. Neuroreport 5 (1994) 2577-2582
30. Morita T., Sakamura Y., Horikiri Y., Suzuki T., and Yoshino H. Protein encapsulation into biodegradable microspheres by a novel S/O/W emulsion method using poly(ethylene glycol) as a protein micronization adjuvant. J. Control. Release 69 (2000) 435-444
31. Mukai S., Kjaergaard J., Shu S., and Plautz G.E. Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res. 59 (1999) 5245-5249
32. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., Bizen A., Honmou O., Niitsu Y., and Hamada H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11 (2004) 1155-1164
33. Nakamura K., Okamura H., Wada M., Nagata K., and Tamura T. Endotoxin-induced serum factor that stimulates gamma interferon production. Infect. Immun. 57 (1989) 590-595
34. Ohtsuki T., Micallef M.J., Kohno K., Tanimoto T., Ikeda M., and Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res. 17 (1997) 3253-3258
35. Osaki T., Peron J.M., Cai Q., Okamura H., Robbins P.D., Kurimoto M., Lotze M.T., and Tahara H. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects. J. Immunol. 160 (1998) 1742-1749
36. Pean J.M., Venier-Julienne M.C., Boury F., Menei P., Denizot B., and Benoit J.P. NGF release from poly(d,l-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. J. Control. Release 56 (1998) 175-187
37. Quattrocchi K.B., Miller C.H., Cush S., Bernard S.A., Dull S.T., Smith M., Gudeman S., and Varia M.A. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J. Neurooncol. 45 (1999) 141-157
38. Raine C.S. Multiple sclerosis: TNF revisited, with promise. Nat. Med. 1 (1995) 211-214
39. Roth W., Isenmann S., Nakamura M., Platten M., Wick W., Kleihues P., Bahr M., Ohgaki H., Ashkenazi A., and Weller M. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61 (2001) 2759-2765
40. Ruegg C.R., Chiquet-Ehrismann R., and Alkan S.S. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 7437-7441
41. Runkel L., Meier W., Pepinsky R.B., Karpusas M., Whitty A., Kimball K., Brickelmaier M., Muldowney C., Jones W., and Goelz S.E. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm. Res. 15 (1998) 641-649
42. Sampson J.H., Archer G.E., Ashley D.M., Fuchs H.E., Hale L.P., Dranoff G., and Bigner D.D. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 10399-10404
43. Soriano I., Evora C., and Llabres M. Preparation and evaluation of insulin-loaded poly(-lactide) microspheres using an experimental design. Int. J. Pharm. 142 (1996) 135-142
44. Tjuvajev J., Gansbacher B., Desai R., Beattie B., Kaplitt M., Matei C., Koutcher J., Gilboa E., and Blasberg R. RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. Cancer Res. 55 (1995) 1902-1910
45. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 (1999) 129-188
46. Weller M., and Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res. Brain Res. Rev. 21 (1995) 128-151
47. Weller M., Kleihues P., Dichgans J., and Ohgaki H. CD95 ligand: lethal weapon against malignant glioma?. Brain Pathol. 8 (1998) 285-293
48. Xiao B.G., and Link H. Immune regulation within the central nervous system. J. Neurol. Sci. 157 (1998) 1-12
49. Yamamoto Y., Kato Z., Matsukuma E., Li A., Omoya K., Hashimoto K., Ohnishi H., and Kondo N. Generation of highly stable IL-18 based on a ligand-receptor complex structure. Biochem. Biophys. Res. Commun. 317 (2004) 181-186